Isabel Kalofonos named ImmunoGen CCO

USA-based company ImmunoGen (Nasdaq: IMGN), a specialist in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Isabel Kalofonos as senior vice president and chief commercial officer.

Ms Kalofonos joins from Swiss dermatology company Galderma, where she was senior vice president and global head of the Prescription Business Unit. During her tenure, she led the launch preparation for nemolizumab, a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research. She also led all commercial franchises of prescription products.

Prior to Galderma, Ms Kalofonos held roles of increasing responsibility at Japanese drugmaker Takeda Pharmaceuticals (TYO: 4502), most recently serving as vice president and head of the hereditary angioedema franchise—a $2.5 billion business.